Rabies
Conditions
Brief summary
Phase II clinical study for an investigational PIKA(Polyinosinic Polycytidylic Acid Based Adjuvant) rabies vaccine comprising Inactivated and Purified Rabies Virus (IPRV) and the PIKA adjuvant. The primary objective of the study is to evaluate the efficacy and safety profile of the vaccine composition in healthy adult volunteers under the accelerated regimen. The secondary objective is to achieve higher seroconversion of the vaccine under accelerated regimen at Day 7.
Detailed description
A multi-center, open labelled, randomized study in healthy naïve adult subjects. Subjects were randomly assigned to groups A (60) and B (60). Group A as a control arm of the study, had received a commercially available rabies vaccine, RABIPUR®. Group B had received doses of the investigational PIKA rabies vaccine in an accelerated regimen. Group A followed the vaccine regimen of (1-1-1-1),one injection on days 0, 3, 7 and 14 was administered respectively. Group B received the accelerated regimen (2-2-1), two injections on both days 0 and 3 were administered in different arms; and only one injection was administered on day 7. Each vaccine dose comprise 1.0 ml of PIKA rabies vaccine for Group B and 1.0 ml of RABIPUR® for Group A after reconstitution. The route of administration is intramuscular injection, given in the deltoid region of the arm.
Interventions
BIOLOGICALRABIPUR®
Biological rabies vaccine
BIOLOGICALPIKA rabies vaccine
Biological rabies vaccine
Sponsors
Yisheng Biopharma (Singapore) Pte. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Informed consent form has been signed and dated * Able to attend all scheduled visits and comply with all trial procedures. * Never received rabies vaccine before. * Refrain from blood donation during the course of the study. * Able to attend all scheduled visits and comply with all trial procedures.
Exclusion criteria
* For women who are pregnant and breast-feeding * Previous vaccination against rabies (in pre- or post-exposure regimen) with either the trial vaccine or another vaccine * History of allergies to the medicine (S), convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction * Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth * Participation in any other interventional clinical trial * Donation of blood within the last 2 months or who have donated plasma within the last 14 days * Patient with clinical signs of encephalitis * Recipient of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination * Planned participation in another clinical trial during the present trial period * Concomitant use or at high probability of expected concomitant use during the planned study of medication such as immune suppressants, steroids, non-study vaccine or similar substances * Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Administration of immunoglobulins and/or any blood products within 3 months prior to the first dose of study vaccine or planned administration during the study period. * History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * Uncontrolled acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history or physical examination. * Chronic administration of immuno-suppressants or other immune-modifying drugs within 3 months prior to the first vaccine dose. * Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Titer level of Rabies Virus Neutralizing Antibody (RVNA) from serum at accelerated regimen | 42 days | Evaluation of the accelerated regimen is studied to check if the levels of anti-rabies antibodies (serum RVNA titer) will be better than a classic course with control commercialized vaccine. |
| Identification of any adverse events for all the treatment groups | 42 days | Assessment of safety based on the identification of any adverse events for all the treatment groups, Group A, Group B and Group C through to the end of the study at day 42. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects in Group B who has higher RVNA titre level on Day 7 when compared to classic course. | Day 7 | To analyze the titer level of RVNA from serum at day 7 after the first injection and with RVNA titer meeting the 0.5 IU(International units) /ml World Health Organization (WHO) requirement |
Countries
Singapore
Outcome results
None listed